Insmed (INSM) Revenue Growth (5y) (2023 - 2026)
Insmed (INSM) Revenue Growth (5y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - |
| 4 | BeOne Medicines | 471.47 Bn | 466.67 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.76 Bn | 114.52 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.15 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - |
| 8 | Argenx Se | 55.77 Bn | 50.59 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.45 Bn | 37.45 Bn | - |
| 10 | Insmed | 22.74 Bn | 21.51 Bn | 258.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.06% |
| Dec 31, 2025 | 44.82% |
| Sep 30, 2025 | 26.67% |
| Jun 30, 2025 | 20.38% |
| Mar 31, 2025 | 20.29% |
| Dec 31, 2024 | 17.97% |
| Sep 30, 2024 | 19.16% |
| Jun 30, 2024 | 24.69% |
| Mar 31, 2024 | 28.08% |
| Dec 31, 2023 | 53.46% |